COMPOSITIONS AND METHODS OF MRNA THERAPEUTICS
The presently described and disclosed technology includes, in one example, a method, comprising: extracting a sequence of a spike protein of a first virus from a first non-human mammal that is previously exposed to an infection by the first virus; identifying a target antigen specific to the spike protein; and injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into a human patient that has antibodies to a second virus.
1 . A method to treat a human patient having antibodies to a first virus, comprising: extracting a sequence of a spike protein of a second virus from at least one first non-human mammal that is previously exposed to an infection by the second virus;
identifying a target antigen specific to the spike protein; and
injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into the human patient.
2 . The method of claim 1 , where each of the first virus and the second virus is a type of coronavirus.
3 . (canceled)
4 . The method of claim 1 , wherein the first virus is SARS-COV-2 virus, and the second virus is SARS-COV-1 virus or wherein the first virus is SARS-COV-1 virus, and the second virus is SARS-COV-2 virus.
5 . (canceled)
6 . The method of claim 1 , wherein the at least one first non-human mammal is a bat, a pangolin, a rodent, or any combinations thereof.
7 . The method of claim 1 , wherein the target antigen is a phylogenetically distant antigen variant of a spike protein of the first virus.
8 . The method of claim 1 , wherein the mRNA therapeutic comprises the mRNA encapsulated in a delivery vehicle composition.
9 . The method of claim 1 , wherein the sequence is selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14.
10 . The method of claim 1 , wherein the second virus is a betacoronavirus.
11 . A method to treat a human patient having antibodies to a first virus, comprising: extracting a sequence of a spike protein of a first virus from at least one human subject that has antibodies with respect to a second virus;
identifying a target antigen specific to the spike protein; and
injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into the human patient.
12 . The method of claim 11 , wherein the human subject and the human patient are not the same person.
13 . The method of claim 11 , wherein the human patient is (a) previously exposed to an infection by the first virus, (b) previously subjected to a vaccination regiment against the first virus, or (c) both.
14 . The method of claim 11 , wherein each of the first virus and the second virus is a type of coronavirus.
15 . (canceled)
16 . The method of claim 11 , wherein the first virus is SARS-COV-2 virus, and the second virus is SARS-COV-1 virus.
17 . The method of at claim 11 , wherein the target antigen is a viral antigen specific to the first virus.
18 . The method of a claim 11 , wherein the mRNA therapeutic comprises the mRNA encapsulated in a delivery vehicle composition.
19 . The method of a claim 11 , wherein the second virus is a betacoronavirus.
20 . The method of claim 11 , wherein the sequence is selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO: 14.
21 . The method of claim 1 , wherein the target antigen is a phylogenetically distant antigen variant of a spike protein of the first virus.
22 . The method of claim 1 , further comprising identifying an antibody sequence adapted to in vivo neutralization of a plurality of strains of the second virus.
23 . The method of claim 11 , wherein the target antigen is a phylogenetically distant antigen variant of a spike protein of the first virus.
24 . The method of claim 11 , further comprising identifying an antibody sequence adapted to in vivo neutralization of a plurality of strains of the second virus.